Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Curr Treat Options Gastroenterol. 2020 Jan 4;18(1):15-32. doi: 10.1007/s11938-019-00259-w. Print 2020 Mar.

Robert Battat^{1

2}, Parambir S Dulai¹, Christopher Ma^{2

3}, Vipul Jairath^{2

4

5}, Brian G Feagan^{2

4

5}, William J Sandborn^{1

2}, Reena Khanna⁶

¹ Division of Gastroenterology and Hepatology, University of California San Diego, La Jolla, CA, USA.
² Robarts Clinical Trials, Inc., 100 Dundas Street, Suite, London, Ontario, Canada.
³ Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
⁴ Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada.
⁵ Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
⁶ Department of Medicine, Division of Gastroenterology, University of Western Ontario, London, Ontario, Canada. rkhanna3@uwo.ca.

Abstract

Note: This statement is mandatory. Please provide.

Keywords: Clinical trial; Endpoints; Outcomes; Remission; Ulcerative colitis.